{"id":12288,"date":"2017-11-22T12:08:46","date_gmt":"2017-11-22T12:08:46","guid":{"rendered":"https:\/\/celonpharma.com\/?page_id=12288"},"modified":"2025-04-04T16:26:33","modified_gmt":"2025-04-04T14:26:33","slug":"publications","status":"publish","type":"page","link":"https:\/\/celonpharma.com\/en\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"<div id=\"container\">\n<section id=\"content\">\n<article id=\"post-775\" class=\"post-775 page type-page status-publish hentry\">\n<div class=\"entry\">\n<div class=\"toc\"><\/div>\n<h2>Articles<\/h2>\n<ul>\n<li>\n<p style=\"text-align: justify;\"><strong><em>Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4<\/em><\/strong><strong><em>, as the candidate for the inhalatory treatment and prevention of Asthma\u00a0<\/em><\/strong>Pawe\u0142 Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G. Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M. Zygmunt ,Maciej Wieczorek, PLOS ONE, July 23, doi.org\/10.1371\/journal.pone.0236159,<\/p>\n<\/li>\n<li>Yamani, A., Zd\u017calik-Bielecka, D., Lipner, J., Sta\u0144czak, A., Pi\u00f3rkowska, N., Sta\u0144czak, P. S., Olejkowska, P., Hucz-Kalitowska, J., Magdycz, M., Dzwonek, K., Dubiel, K., Lamparska-Przybysz, M., Popiel, D., Pieczykolan, J., &amp; Wieczorek, M. <strong>(2020)<\/strong>. Discovery and Optimization of Novel Pyrazole-Benzimidazole CPL304110, as a Potent and Selective Inhibitor of Fibroblast Growth Factor Receptors FGFR (1-3). <em>European Journal of Medicinal Chemistry<\/em>, 112990. <a href=\"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112990\">https:\/\/doi.org\/10.1016\/j.ejmech.2020.112990<\/a><\/li>\n<li>Hogendorf, A. S., Hogendorf, A., Kurczab, R., Kalinowska-T\u0142u\u015bcik, J., Popik, P., Nikiforuk, A., Krawczyk, M., Sata\u0142a, G., Lenda, T., Knutelska, J., Bugno, R., Staro\u0144, J., Pietru\u015b, W., Mat\u0142oka, M., Dubiel, K., Moszczy\u0144ski-P\u0119tkowski, R., Pieczykolan, J., Wieczorek, M., Pilarski, B., \u2026 Bojarski, A. J<strong>. (2019)<\/strong>. 2-Aminoimidazole-based antagonists of the 5-HT6 receptor \u2013 A new concept in aminergic GPCR ligand design. <em>European Journal of Medicinal Chemistry<\/em>, <em>179<\/em>, 1\u201315. <a href=\"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.001\">https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.001<\/a><\/li>\n<li>Staro\u0144, J., Kurczab, R., Warszycki, D., Sata\u0142a, G., Krawczyk, M., Bugno, R., Lenda, T., Popik, P., Hogendorf, A. S., Hogendorf, A., Dubiel, K., Mat\u0142oka, M., Moszczy\u0144ski-P\u0119tkowski, R., Pieczykolan, J., Wieczorek, M., Zajdel, P., &amp; Bojarski, A. J. <strong>(2019).<\/strong> Virtual screening-driven discovery of dual 5-HT6\/5-HT2A receptor ligands with pro-cognitive properties. <em>European Journal of Medicinal Chemistry<\/em>, 111857. <a href=\"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111857\">https:\/\/doi.org\/10.1016\/j.ejmech.2019.111857<\/a><\/li>\n<li>Moszczy\u0144ski-P\u0119tkowski, R., Majer, J., Borkowska, M., Bojarski, \u0141., Janowska, S., Mat\u0142oka, M., Stefaniak, F., Smuga, D., Bazyd\u0142o, K., Dubiel, K., &amp; Wieczorek, M. <strong>(2018).<\/strong> Synthesis and characterization of novel classes of PDE10A inhibitors &#8211; 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines. <em>European Journal of Medicinal Chemistry<\/em>, <em>155<\/em>, 96\u2013116. <a href=\"https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.043\">https:\/\/doi.org\/10.1016\/j.ejmech.2018.05.043<\/a><\/li>\n<li><strong>Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors<\/strong> <span style=\"text-decoration: underline;\">Pawel Gunerka; \u00a0Barbara Dymek; Aleksandra Stanczak; Anna Bujak; Paulina Grygielewicz; Pawel Turowski; Karolina Dzwonek; Monika Lamparska-Przybysz; Tadeusz Pietrucha; Maciej Wieczorek,\u00a0<\/span>European Journal of Pharmacology Volume 765, 15 October 2015, Pages 188\u2013197 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0doi:10.1016\/j.ejphar.2015.08.037<\/li>\n<\/ul>\n<ul class=\"block\">\n<li><strong>Discovery of TRAF-2 and NCK-interacting kinase (TNIK) inhibitors by ligand-based virtual screening methods.<\/strong> <span style=\"text-decoration: underline;\">Anna Bujak, Filip Stefaniak, Daria Zdzalik, Paulina Grygielewicz, Barbara Dymek, Marcin Zagozda, Pawel Gunerka, Monika Lamparska-Przybysz, Krzysztof Dubiel, Maciej Wieczorek, Karolina Dzwonek <\/span>Med.Chem.Commun. 2015, 6,1564\u20131572\u00a0\u00a0 Accepted 24th June 2015\u00a0\u00a0 DOI: 10.1039\/c5md00090d<\/li>\n<li><strong>Cell-based assay for low- and high-scale screening of the Wnt\/b-catenin signaling modulators<\/strong> <span style=\"text-decoration: underline;\">Mazur M, Bujak A, Matloka M, Janowska S, Gunerka P, Bojarski L, Stanczak A, Kerman A, Bednarek A, Lamparska-Przybysz M, Wieczorek M. <\/span>Anal Biochem. 2015 Apr 15;475:56-67. doi: 10.1016 \/ j.ab.2015.01.016.<\/li>\n<li><strong>Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells<\/strong>, <span style=\"text-decoration: underline;\">Grygielewicz P1, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K, Zdzalik D,<\/span> Gastric Cancer 2014 Nov 19<\/li>\n<li><strong>Wnt\/\u03b2-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.<\/strong>, Bodnar L, <span style=\"text-decoration: underline;\">Stanczak A,<\/span> Cierniak S, Smoter M, Cichowicz M, Kozlowski W, Szczylik C, <span style=\"text-decoration: underline;\">Wieczorek M, Lamparska-Przybysz M. J,<\/span> Ovarian Res. 2014 Feb 6;7:16.<\/li>\n<li><strong>Drugs from a computer<\/strong>, <span style=\"text-decoration: underline;\">Stefaniak F, Zd\u017calik D, Dymek B<\/span>, Przemys\u0142 Farmaceutyczny 1\/2014<\/li>\n<li><strong>Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.<\/strong>, <span style=\"text-decoration: underline;\">Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K.<\/span>, J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98<\/li>\n<li><strong>Comparative analysis of inhaler\u2019s internal resistance in Salmex\u2122, a generic drug and its refernce product \u2013 Seretide\u2122<\/strong>, <span style=\"text-decoration: underline;\">P\u0105czkowska E, St\u0119pie\u0144-Baran A, Wieczorek M<\/span>, <a title=\"www.praktykalekarska.com\" href=\"http:\/\/www.praktykalekarska.com\" target=\"_blank\" rel=\"noopener\">Praktyka Lekarska<\/a> 2013; 8 (98): 18-20<\/li>\n<li><strong>To hit the mark<\/strong>, <span style=\"text-decoration: underline;\">Lamparska-Przybysz M, Dzwonek K, Bojarski L<\/span>, Przemys\u0142 Farmaceutyczny 5\/2012<\/li>\n<li><strong>Prognostic significance of Wnt-1, \u00df-catenin and E-cadherin expression in advanced colorectal carcinoma,<\/strong><span style=\"text-decoration: underline;\">Stanczak A<\/span>, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, <span style=\"text-decoration: underline;\">Wieczorek<\/span><span style=\"text-decoration: underline;\"> M<\/span>, <span style=\"text-decoration: underline;\">Lamparska-Przybysz M<\/span>, Pathol Oncol Res. 2011 Dec;17(4):955-63.<\/li>\n<li><strong>Before the drug is administered to a human subject for the first time \u2013 guidelines and legal regulations on preclinical trials,\u00a0<\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span>, Przemys\u0142 Farmaceutyczny nr 6\/2011<\/li>\n<li><strong>In vitro findings of alterations in intracellular calcium homeostasis in schizophrenia<\/strong>, <span style=\"text-decoration: underline;\">Bojarski L<\/span><span style=\"text-decoration: underline;\">, <\/span>Debowska K, Wojda U., Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1367-74.<\/li>\n<li><strong>Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells, <\/strong><span style=\"text-decoration: underline;\">Wieczorek M, Paczkowska A, Guzenda P, Majorek M, Bednarek AK, Lamparska-Przybysz M.<\/span> . Cancer Biol Ther. 2008 Feb;7(2):268-74.<\/li>\n<li><strong>Role of Wnt\/\u03b2-catenin pathway in molecular mechanism of tumorigenesis,\u00a0<\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz, Maciej Wieczorek, Maria Majorek, Piotr Guzenda,<\/span> Wsp\u00f3\u0142czesna Onkologia 2006; 10: 497-501 [article in Polish]<\/li>\n<li><strong>siRNA technology \u2013 a chance for a breakthroigh in cancer treatment,\u00a0<\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz,<\/span> Przemys\u0142 farmaceutyczny 2\/2006 [article in Polish]<\/li>\n<li><strong>Molecular mechanism of action of siRNA<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz, Piotr Guzenda<\/span>. Praktyka lekarska 2006; 11(24) [article in Polish]<\/li>\n<li><strong>Small interfering RNA in oncology<\/strong>, <span style=\"text-decoration: underline;\">Maria Majorek, Piotr Guzenda, Monika Lamparska-Przybysz, Maciej Wieczorek,<\/span> Wsp\u00f3\u0142czesna Onkologia 2006; 8(10): 367-372 [article in Polish]<\/li>\n<li><strong>siRNA as a therapeutic tool<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz, Piotr Guzenda, <\/span> Praktyka lekarska 2006; 10(23) [article in Polish]<\/li>\n<li><strong>Polish Alzheimer\u2019s drug<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span>, Praktyka lekarska 2006; 9(22) [article in Polish]<\/li>\n<li><strong>Stem cells in treatment<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz,<\/span> Praktyka lekarska 2006; 8(21) [article in Polish]<\/li>\n<li><strong>A breakthrough in treating allergies?, <\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz,<\/span> Praktyka lekarska 2006; 7(20) [article in Polish]<\/li>\n<li><strong>Modern techniques of delivering drugs to cancer cells, <\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span>, Praktyka lekarska 2006; 6(19) [article in Polish]<\/li>\n<li><strong>Diagnostics of chromosomal abnormalities with the use of the FISH technique, <\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span>, Praktyka lekarska 2006; 5(8) [article in Polish]<\/li>\n<li><strong>The time of technologies in cancer treatment, <\/strong><span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span>, Praktyka lekarska 2006; 4(17) [article in Polish]<\/li>\n<li><strong>Microarrays \u2013 a tool for diagnosis and study of molecular mechanisms behind the origin of cancer<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz,<\/span> Praktyka lekarska 2006; 3(16) [article in Polish]<\/li>\n<li><strong>The use of monoclonal antibodies in treatment<\/strong>, Monika Lamparska-Przybysz, Praktyka lekarska 2006; 2(15) [article in Polish]<\/li>\n<\/ul>\n<h2>Oral communications<\/h2>\n<ul class=\"block\">\n<li><strong>About a few problems which cannot be solved without interfacial catalysis<\/strong>, <span style=\"text-decoration: underline;\">Filip Stefaniak<\/span>, Micha\u0142 Fedory\u0144ski; <a title=\"PTChem 2013\" href=\"http:\/\/www.ptchem2013.uph.edu.pl\" target=\"_blank\" rel=\"noopener\">56. Zjazd Polskiego Towarzystwa Chemicznego<\/a>, Siedlce, September 2013<\/li>\n<li><strong>Design and development of CPL-407-22 \u2013 novel, potent and selective JAK2 protein kinase inhibitor<\/strong>, <span style=\"text-decoration: underline;\">Filip Stefaniak, Karolina Dzwonek, Micha\u0142 Mroczkiewicz, Joanna Paradowska, Bartosz Stypik, Pawel Gunerka, Daria Zdzalik, Barbara Dymek, Paulina Grygielewicz,Monika Lamparska-Przybysz, Maciej Wieczorek<\/span>; <a title=\"VIII MULTIDYSCYPLINARNA KONFERENCJA NAUKI O LEKU\" href=\"http:\/\/science24.com\/event\/mknol2012\/\" target=\"_blank\" rel=\"noopener\">VIII <\/a><a title=\"VII Multidyscyplinarna Konferencja Nauki o Leku\" href=\"http:\/\/science24.com\/event\/mknol2010\/\" target=\"_blank\" rel=\"noopener\">Multidyscyplinarna Konferencja Nauki o Leku<\/a>, Ossa, June 2012<\/li>\n<li><strong>CPL-200-075, a novel potent renal sodium-glucose cotransporter 2 (SGLT2) inhibitor<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span><span style=\"text-decoration: underline;\">, Piotr Guzenda, Joanna Hucz-Kalitowska, Mateusz Mach, Micha\u0142 Mroczkiewicz, Katarzyna Bazyd\u0142o, Krzysztof Dubiel, Maciej Wieczorek<\/span>; <a title=\"VIII MULTIDYSCYPLINARNA KONFERENCJA NAUKI O LEKU\" href=\"http:\/\/science24.com\/event\/mknol2012\/\" target=\"_blank\" rel=\"noopener\">VIII <\/a><a title=\"VII Multidyscyplinarna Konferencja Nauki o Leku\" href=\"http:\/\/science24.com\/event\/mknol2010\/\" target=\"_blank\" rel=\"noopener\">Multidyscyplinarna Konferencja Nauki o Leku<\/a>, Ossa, June 2012<\/li>\n<li><strong>Development of Alzheimer\u2019s drugs \u2013 what we learned from failures in clinical trias<\/strong>., <span style=\"text-decoration: underline;\">\u0141ukasz Bojarski<\/span>, Sympozjum: Choroby neurodegeneracyjne:mechanizmy molekularne i nowe strategie terapeutyczne, Warsaw, October 2011<\/li>\n<li><strong>Hopes and pitfalls of neuroprotective drugs development. The lesson of Alzheimer\u2019s disease<\/strong>, <span style=\"text-decoration: underline;\">\u0141ukasz Bojarski<\/span>, The 11th International Neurochemical Symposium, Warsaw, October 2011<\/li>\n<li><strong>Novel small molecule STAT3 inhibitors in cancer therapy<\/strong>, <span style=\"text-decoration: underline;\"> Karolina Dzwonek, Filip Stefaniak, Pawe\u0142 Gunerka, Monika Lamparska-Przybysz<\/span>; <a title=\"VII Multidyscyplinarna Konferencja Nauki o Leku\" href=\"http:\/\/science24.com\/event\/mknol2010\/\" target=\"_blank\" rel=\"noopener\">VII Multidyscyplinarna Konferencja Nauki o Leku<\/a>; Zakopane, May 2010<\/li>\n<li><strong>RNAi &#8211; breakthrough technology gives hope for breakthrough therapeutics.<\/strong> <span style=\"text-decoration: underline;\">Maria G. Majorek, Monika Gutowska, Joanna Hucz, Monika Lamparska-Przybysz,<\/span><span style=\"text-decoration: underline;\">Maciej Wieczorek<\/span>; <a title=\"VII Multidyscyplinarna Konferencja Nauki o Leku\" href=\"http:\/\/science24.com\/event\/mknol2010\/\" target=\"_blank\" rel=\"noopener\">VII Multidyscyplinarna Konferencja Nauki o Leku<\/a>; Zakopane, May 2010<\/li>\n<li><strong>Knowledge-based design of a novel selective pan-FGFR kinase inhibitor &#8211; CELONKO project,<\/strong> <span style=\"text-decoration: underline;\">Aleksandra Sta\u0144czak<\/span>; 2nd Central European Biomedical Congress, Krak\u00f3w, 2016<\/li>\n<\/ul>\n<h2>Posters<\/h2>\n<ul class=\"block\">\n<li><strong>CPL-500-012 &#8211; a novel selective and potent inhibitor of phosphodiesterase 10 with antipsychotic activity in animals models<\/strong> <span style=\"text-decoration: underline;\">Matloka M., Janowska S., Moszczynski-Petkowski R., Majer J., Borkowska M., Kos T., Holuj M., Lamparska- Przybysz M., Dubiel K., Popik P., Wieczorek M., Bojarski L <\/span>GRC Cyclic Nucleotide Phosphodiesterases Signaling, South Hadley, czerwiec 2014<\/li>\n<li><strong>Characterization of a novel group of phosphodiesterase 9A inhibitors as putative therapeutic for cognitive dysfunction<\/strong> <span style=\"text-decoration: underline;\">Mat\u0142oka M., Janowska S., Moszczy\u0144ski R., Majer J., Borkowska M., Boguszewski P., Zd\u017calik D., Hucz-Kalitowska J., Stefaniak F., Lamparska-Przybysz M., Dubiel K., Wieczorek M., Bojarski \u0141. <\/span>, Kopenhaga, lipiec 2014<\/li>\n<li><strong>Preclinical evaluation of a novel highly potent and selective PI3K-delta inhibitor CPL-302-201 for the treatment of hematologic malignancies<\/strong> <span style=\"text-decoration: underline;\">Dymek B, Zdzalik D, Zagozda M, Dziachan M, Malczyk M, Bujak A, Grygielewicz P, Gunerka P, Musielak O, Skupinska M, Hucz-Kalitowska J, Dubiel K, Lamparska-Przybysz M, Wieczorek M, Stanczak A. <\/span> 19th Congress of the European Hematology Association, Milan, Italy, 12-15.06.2014.<\/li>\n<li><strong>Preclinical characterization of CPL-302-201, a novel, highly potent and selective<br \/>\nPI3K\u03b4 inhibitor for the treatment of inflammatory disorders<\/strong> <span style=\"text-decoration: underline;\">Barbara Dymek, Olga Musielak, Pawel Gunerka, Daria Zdzalik, Marcin Zagozda, Maciej Dziachan, Maciej Malczyk, Anna Bujak, Paulina Grygielewicz,Monika Skupinska, Joanna Hucz-Kalitowska, Krzysztof Dubiel, Monika Lamparska-Przybysz, Maciej Wieczorek, Aleksandra Stanczak<\/span><\/li>\n<li><strong>Therapeutic potential of CPL-407-105: a novel, potent JAK\/STAT pathway inhibitor for the treatment of asthma<\/strong> <span style=\"text-decoration: underline;\">Pawe\u0142 Gunerka, Barbara Dymek, Daria Zdzalik, Micha\u0142 Mroczkiewicz, Joanna Lipner, Bartosz Stypik, Anna Bujak, Paulina Grygielewicz, Olga Musielak, Monika Skupi\u0144ska, Joanna Hucz-Kalitowska, Krzysztof Dubiel, Monika Lamparska-Przybysz, Maciej Wieczorek, Aleksandra Stanczak<\/span><\/li>\n<li><strong>Epithelial-mesenchymal transition confers resistance to FGFR inhibitors in gastric cancer cell line<\/strong> <span style=\"text-decoration: underline;\">Paulina Grygielewicz, Daria Zd\u017calik, Barbara Dymek, Anna Bujak, Pawe\u0142 Gunerka, Aleksandra Sta\u0144czak, Monika Lamparska-Przybysz, Maciej Wieczorek, Karolina Dzwonek.<\/span> <a href=\"http:\/\/eccamsterdam2013.ecco-org.eu\/\">The European Cancer Congress 2013<\/a>, Amsterdam<\/li>\n<li><strong>Design and development of active and selective FGFR kinase inhibitor CPL-043 as potential anticancer targeted therapy <\/strong> <span style=\"text-decoration: underline;\">Daria Zd\u017calik, Paulina Grygielewicz, Joanna Lipner, Anna Bujak, Barbara Dymek, Pawe\u0142 Gunerka, Aleksandra Sta\u0144czak, Joanna Hucz-Kalitowska, Monika Lamparska-Przybysz, Maciej Wieczorek, Karolina Dzwonek.<\/span> <a href=\"http:\/\/eccamsterdam2013.ecco-org.eu\/\">The European Cancer Congress 2013<\/a>, Amsterdam<\/li>\n<li><strong>Discovery of novel GSK3beta inhibitor lead structure using sequential virtual screening.\u00a0<\/strong><span style=\"text-decoration: underline;\">Sylwia Janowska, Filip Stefaniak, \u0141ukasz Bojarski, Rafa\u0142 Moszczy\u0144ski-P\u0119tkowski, Malgorzata Borkowska, Jakub Majer, Miko\u0142aj Mat\u0142oka, Krzysztof Dubiel, Monika Lamparska-Przybysz, Maciej Wieczorek<\/span> <a href=\"http:\/\/www2.kenes.com\/adpd\/Pages\/Home.aspx\">AD\/PD, Florence 2013<\/a><\/li>\n<li><strong>Discovery of CPL-407-22 &#8211; novel, potent and highly selective JAK2 kinase inhibitor.<\/strong> <span style=\"text-decoration: underline;\">Karolina Dzwonek, Micha\u0142 Mroczkiewicz, Filip Stefaniak, Pawel Gunerka, Daria Zdzalik, Barbara Dymek, Paulina Grygielewicz, Joanna Paradowska, Bartosz Stypik, Monika Lamparska-Przybysz, Maciej Wieczorek<\/span> <a href=\"http:\/\/www.ecco-org.eu\/Conferences\/Conferences\/EORTC_NCI_AACR-2012\/Welcome-message.aspx\">EORTC, Dublin 2012<\/a><\/li>\n<li><strong>Differential gene transcription response to the treatment with JAK2 inhibitors \u2013 Ruxolitinib, SAR302503 and LY2784544<\/strong>. <span style=\"text-decoration: underline;\">Pawel Gunerka, Barbara Dymek, Daria Zdzalik, Paulina Grygielewicz, Karolina Dzwonek, Monika Lamparska-Przybysz, Maciej Wieczorek<\/span> <a href=\"http:\/\/eacr22.eacr.org\/\">EACR, Barcelona 2012<\/a><\/li>\n<li><strong>NPM-ALK I1171T mutation confers resistance to crizotinib in anaplastic large cell lymphoma.<\/strong>. <span style=\"text-decoration: underline;\">Daria Zdzalik, Barbara Dymek, Pawe\u0142 Gunerka, Paulina Grygielewicz, Karolina Dzwonek, Monika Lamparska-Przybysz, Maciej Wieczorek<\/span> <a href=\"http:\/\/eacr22.eacr.org\/\">EACR, Barcelona 2012<\/a><\/li>\n<li><strong>Gene silencing of \u00df-catenin inhibits growth of Wnt\/\u00df-catenin pathway dependent colon cancer cell lines.<\/strong> <span style=\"text-decoration: underline;\">Anna Bujak, Miko\u0142aj Mat\u0142oka, Monika Skupi\u0144ska, Maria Mazur, Monika Lamparska-Przybysz, Maciej Wieczorek<\/span> <a href=\"http:\/\/eacr22.eacr.org\/\">EACR, Barcelona 2012<\/a><\/li>\n<li><strong>CPL-204-015 inhibits phosphodiesterase 9A activity and improves cognition in rat social recognition model of natural forgetting.<\/strong><span style=\"text-decoration: underline;\"> \u0141ukasz Bojarski, Rafa\u0142 Moszczy\u0144ski-P\u0119tkowski<\/span>, Pawe\u0142 M. Boguszewski, <span style=\"text-decoration: underline;\">Ma\u0142gorzata Borkowska, Sylwia Janowska, Katarzyna Grab, Krzysztof Dubiel, Monika Lamparska-Przybysz, Maciej Wieczorek.<\/span> 12th International Stockholm\/ Springfield Symposium on Advances on Alzheimer Therapy, Stocholm 2012<\/li>\n<li><strong>Prognostic role of Wnt\/Beta-catenin pathway in colorectal carcinoma, <\/strong>A<span style=\"text-decoration: underline;\">leksandra Stanczak<\/span>, Rafal Stec, Lubomir Bodnar, Wojciech Olszewski, Marzena Cichowicz, Wojciech Kozlowski, Cezary Szczylik, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz<\/span>,<span style=\"text-decoration: underline;\"> Maciej Wieczorek,<\/span> <strong style=\"font: inherit;\">Molecular Targets and Cancer Therapeutics<\/strong>Conference, Boston 2010<\/li>\n<li><strong>Inhibition of ErbB receptor in breast cancer cell lines using small interfering RNA (siRNA)<\/strong>, <span style=\"text-decoration: underline;\">Maria Majorek, Maciej Wieczorek, Piotr Guzenda, Aleksandra P\u0105czkowska, Monika Lamparska-Przybysz.<\/span> Cancer Therapeutics: The Road Ahead, Capri 2007<\/li>\n<li><strong>Silencing of the expression of an antiapoptotic protein in cancer treatment &#8211; Preclinical data. <\/strong><span style=\"text-decoration: underline;\">Piotr Guzenda, Aleksandra P\u0105czkowska, Maria Majorek, Maciej Wieczorek, Monika Lamparska-Przybysz<\/span>. SENECA Conference, Warsaw 2007<\/li>\n<li><strong>Downregulation of Wnt1 by siRNA induces apoptosis of breast cancer cells<\/strong>, <span style=\"text-decoration: underline;\">Monika Lamparska-Przybysz, Aleksandra P\u0105czkowska, Piotr Guzenda, Maria Majorek, Maciej Wieczorek<\/span>. ECCO14 Conference, Barcelona 2007<\/li>\n<li><strong>Silencing of the expression of an antiapoptotic protein in cancer treatment \u2013 Preclinical data<\/strong>, <span style=\"text-decoration: underline;\">Piotr Guzenda, Maria Majorek, Aleksandra P\u0105czkowska, Monika Lamparska-Przybysz, Maciej Wieczorek<\/span>, RNAi Europe Conference , Oxford 2007<\/li>\n<li><strong>Transfection efficiency and cytotoxicity of commonly used siRNA transfection reagents. <\/strong><span style=\"text-decoration: underline;\">Maria Majorek, Monika Lamparska-Przybysz, Piotr Guzenda, Maciej Wieczorek, <\/span><strong style=\"font: inherit;\">RNAi Europe Conference, <\/strong>Prague 2006<\/li>\n<li><strong>Preclinical data with siRNA targeting WNT1 mRNA for breast cancer treatment. <\/strong><span style=\"text-decoration: underline;\">Maciej Wieczorek, Monika Lamparska-Przybysz, Maria Majorek, Piotr Guzenda,<\/span> RNAi Europe Conference. Prague 2006<\/li>\n<li><strong>Development of siRNA-based method for suppressing of tumor cell growth<\/strong>, Nasulewicz A., Szczaurska K., <span style=\"text-decoration: underline;\">Guzenda P<\/span>., Wietrzyk J., Bednarek A., <span style=\"text-decoration: underline;\">Wieczorek M<\/span>. . IV International Symposium on Targeted Anticancer Therapies, Amsterdam 2006<\/li>\n<li><strong>Analysis of the intra-tumor heterogeneity and consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer,<\/strong> <span style=\"text-decoration: underline;\">Skupinska M. , P. Jagus,\u00a0 Grygielewicz P., Mikolajczyk A., Szczepulska E. , Rozy A. ,Langfort R., Chorostowska-Wynimko J.,\u00a0 Wieczorek M., A. Stanczak,<\/span>16th World Conference on Lung Cancer, Colorado 2015<\/li>\n<li><strong>Preclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as a potential anticancer targeted therapy,<\/strong> <span style=\"text-decoration: underline;\">Grygielewicz P., Piorkowska N., Miko\u0142ajczyk A., Hucz-Kalitowska J., Yamani A., Dubiel K., Wieczorek M., Stanczak A.<\/span> 10th Protein Kinases in Drug Discovery Conference, Berlin 2015<\/li>\n<li><strong>Design and development of a novel, highly potent and selective pi3k-delta inhibitor,<\/strong> CPL-302-215, as potential treatment of hematologic malignancies,<span style=\"text-decoration: underline;\"> Stanczak A., Dymek\u00a0B., Turowski P., Gunerka\u00a0P., Zagozda M., Dziachan\u00a0M., Sekular M., Szydlowski M., Bialopiotrowicz E., Juszczy\u0144ski P.,\u00a0 Hucz-Kalitowska J., Dubiel K., Wieczorek M.<\/span>, 20th European Hematology Association Conference, Vienna 2015<\/li>\n<\/ul>\n<\/div>\n<\/article>\n<\/section>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Articles Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma\u00a0Pawe\u0142 Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G. Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M. Zygmunt ,Maciej Wieczorek, PLOS ONE, July 23, doi.org\/10.1371\/journal.pone.0236159,<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/publications\/\" title=\"ReadPublications\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":20,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-publications.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-12288","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Publications - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Articles Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma\u00a0Pawe\u0142 Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G. Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M. Zygmunt ,Maciej Wieczorek, PLOS ONE, July 23, doi.org\/10.1371\/journal.pone.0236159,Read more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-04T14:26:33+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/publications\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/publications\\\/\",\"name\":\"Publications - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2017-11-22T12:08:46+00:00\",\"dateModified\":\"2025-04-04T14:26:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/publications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/publications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/publications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/publications\/","og_locale":"en_US","og_type":"article","og_title":"Publications - Celon Pharma","og_description":"Articles Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of Asthma\u00a0Pawe\u0142 Gunerka, Kamila Gala, Martyna Banach, Jakub Dominowski, Joanna Hucz-Kalitowska, Krzysztof Mulewski, Agnes Hajnal, Endre G. Mikus, Damian Smuga, Marcin Zagozda, Krzysztof Dubiel, Jerzy Pieczykolan, Beata M. Zygmunt ,Maciej Wieczorek, PLOS ONE, July 23, doi.org\/10.1371\/journal.pone.0236159,Read more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/publications\/","og_site_name":"Celon Pharma","article_modified_time":"2025-04-04T14:26:33+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/publications\/","url":"https:\/\/celonpharma.com\/en\/publications\/","name":"Publications - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2017-11-22T12:08:46+00:00","dateModified":"2025-04-04T14:26:33+00:00","breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/publications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages\/12288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=12288"}],"version-history":[{"count":8,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages\/12288\/revisions"}],"predecessor-version":[{"id":18157,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/pages\/12288\/revisions\/18157"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=12288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}